117 related articles for article (PubMed ID: 10697501)
21. In pursuit of antisense.
Matteucci MD; Wagner RW
Nature; 1996 Nov; 384(6604 Suppl):20-2. PubMed ID: 8895596
[TBL] [Abstract][Full Text] [Related]
22. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
[TBL] [Abstract][Full Text] [Related]
23. Antisense oligonucleotides for central nervous system tumors.
Hall WA; Flores EP; Low WC
Neurosurgery; 1996 Feb; 38(2):376-83. PubMed ID: 8869067
[TBL] [Abstract][Full Text] [Related]
24. Sugar boost: when ribose modifications improve oligonucleotide performance.
Faria M; Ulrich H
Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
[TBL] [Abstract][Full Text] [Related]
25. The disposition (ADME) of antisense oligonucleotides.
Dvorchik BH
Curr Opin Mol Ther; 2000 Jun; 2(3):253-7. PubMed ID: 11249618
[TBL] [Abstract][Full Text] [Related]
26. Application of antisense oligodeoxynucleotides (ODNs) for the intervention of kidney disease. Antisense ODNs for transforming growth factor-beta-suppressed glomerulosclerosis in experimental glomerulonephritis.
Imai E; Isaka Y; Akagi Y; Arai M; Moriyama T; Takenaka M; Kaneko T; Horio M; Ando A; Orita Y; Kaneda Y; Ueda N; Kamada T
Contrib Nephrol; 1996; 118():86-93. PubMed ID: 8744044
[No Abstract] [Full Text] [Related]
27. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
28. [Antisense against cancer?]].
Edris E; Möller AM; Oberhauser EM; Zündorf I; Dingermann T
Pharm Unserer Zeit; 2010 May; 39(3):170-1. PubMed ID: 20425764
[No Abstract] [Full Text] [Related]
29. Antisense oligonucleotide therapy in cancer.
Stephens AC; Rivers RP
Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
[TBL] [Abstract][Full Text] [Related]
30. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
31. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles.
Föger F; Noonpakdee W; Loretz B; Joojuntr S; Salvenmoser W; Thaler M; Bernkop-Schnürch A
Int J Pharm; 2006 Aug; 319(1-2):139-46. PubMed ID: 16713146
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide.
Yonemura Y; Endo Y; Fujita H; Kimura K; Sugiyama K; Momiyama N; Shimada H; Sasaki T
J Exp Clin Cancer Res; 2001 Jun; 20(2):205-12. PubMed ID: 11484976
[TBL] [Abstract][Full Text] [Related]
34. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
[TBL] [Abstract][Full Text] [Related]
35. Synthetic oligonucleotides as therapeutics: the coming of age.
Ma DD; Rede T; Naqvi NA; Cook PD
Biotechnol Annu Rev; 2000; 5():155-96. PubMed ID: 10875000
[TBL] [Abstract][Full Text] [Related]
36. Prospects for gene-directed therapy with antisense oligodeoxynucleotides.
Calabretta B; Skorski T; Szczylik C; Zon G
Cancer Treat Rev; 1993 Apr; 19(2):169-79. PubMed ID: 8481928
[No Abstract] [Full Text] [Related]
37. [Treatment of malignant diseases with synthetic oligonucleotides].
Rechavi G; Mandel M
Harefuah; 1992 Aug; 123(3-4):133-8. PubMed ID: 1516865
[No Abstract] [Full Text] [Related]
38. Use of antisense vectors and oligodeoxynucleotides in neuro-oncology.
Engelhard HH; Egli M; Rozental JM
Pediatr Neurosurg; 1998 Jun; 28(6):279-85. PubMed ID: 9782204
[No Abstract] [Full Text] [Related]
39. Making sense out of anti-sense: challenges of imaging gene translation with radiolabeled oligonucleotides.
Piwnica-Worms D
J Nucl Med; 1994 Jun; 35(6):1064-6. PubMed ID: 8195871
[No Abstract] [Full Text] [Related]
40. Molecular intervention with antisense oligodeoxynucleotides (ODNs) in nephrology.
Imai E; Akagi Y; Isaka Y
Nephrol Dial Transplant; 1997 Nov; 12(11):2213-5. PubMed ID: 9394298
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
